Medical Group will be first in U.S. to offer BreastSentry® diagnostic test
TORONTO, March 16, 2017 /CNW/ - GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announced today that it has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests. The contract represents the second partnership agreement with a U.S. healthcare services group and will mark the introduction of GeneNews' BreastSentry® diagnostic test to the U.S. market.
Patients of this medical group, which prefers not to have its name published, will now have access to GeneNews' innovative screening tests – ColonSentry®, earlyCDT®-Lung, Prostate Health Index, and the new BreastSentry® diagnostic test – which provide early risk stratification of colorectal cancer, lung cancer, prostate cancer and breast cancer, respectively. All four screenings utilize a quick and convenient blood test that can be completed through designated medical clinics.
GeneNews will process the samples through its CAP and CLIA-certified Innovative Diagnostic Laboratory ("IDL") clinical reference laboratory in Richmond, Virginia, and provide individualized risk stratification reports for each patient, the supply of testing kits and ongoing consultation. JTS Health Partners, based in Atlanta, Georgia, will work with both GeneNews and the medical group within the planning and implementation phase.
"We are pleased to partner with this leading physician group, which will be the first to offer our BreastSentry® diagnostic, a blood test that predicts a patient's risk of developing breast cancer in the ensuing five years, as well as estimating life time risk," commented James R Howard-Tripp. "As with most cancers, the early identification of high risk patients is critical to improved decision making and treatment. We are confident that this test will be well-received by patients and look forward to making it more widely available throughout the United States in the coming months.
GeneNews is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health out-comes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for the four most prevalent cancer types - colon, lung and prostate. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews can be found at www.GeneNews.com.
About JTS Health Partners
The Company is partnered with JTS Health Partners of Atlanta, Georgia. Their healthcare management consulting and services portfolio is focused on enterprise advisory planning, health information management, information technology, financial and revenue cycle management. More information on JTS can be found at www.jtshealthpartners.com.
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
SOURCE GeneNews Limited
For further information: Company Contact: James R. Howard-Tripp, Chairman & CEO, Office: (905) 209-2030, firstname.lastname@example.org; Investor & Media Contact: Stephen Kilmer, Office: (212) 618-6347, Mobile: (647) 872-4849, email@example.com